🇺🇸 paricalcitol capsules in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Thrombosis — 2 reports (18.18%)
2. Anaemia — 1 report (9.09%)
3. Bacteraemia — 1 report (9.09%)
4. Epistaxis — 1 report (9.09%)
5. Full Blood Count Decreased — 1 report (9.09%)
6. Leukopenia — 1 report (9.09%)
7. Mouth Haemorrhage — 1 report (9.09%)
8. Pruritus — 1 report (9.09%)
9. Pulmonary Embolism — 1 report (9.09%)
10. Skin Discolouration — 1 report (9.09%)

Source database →

Frequently asked questions

Is paricalcitol capsules approved in United States?

paricalcitol capsules does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for paricalcitol capsules in United States?

Abbott is the originator. The local marketing authorisation holder may differ — check the official source linked above.